Corindus Vascular Robotics

Press release

May 09, 2016

Corindus Vascular Robotics Announces Additions to Management Team

Doug Teany Named Senior Vice President of Research & Development and Operations
Nora Dutta Named Vice President of Human Resources

WALTHAM, MA - May 9, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced the addition of two experienced leaders in the medical device industry to the Company’s management team.

Doug Teany was named Senior Vice President of Research & Development and Operations, effective March 21, 2016. Mr. Teany has an 18-year track record of driving operational excellence in the medical device and pharmaceutical industries. He joins Corindus from East River Consulting Group where he specialized in scaling operations for emerging medical device companies. Previously, Mr. Teany served as Vice President in Boston Scientific’s Research & Development organization, responsible for strategy and operations of its global clinical and preclinical research functions. During his tenure at Boston Scientific, Mr. Teany played a key role in returning the company to profitability, contributing significantly to operating income growth through product development optimization and operational performance improvement. He designed and led numerous organizational transformations, improved operations for multiple large-scale laboratory and research facilities and optimized the performance of pivotal development programs such as the Promus Element™ Stent and Lotus™ Valve TAVI Systems.
Nora Dutta was named Vice President, Human Resources, effective April 25, 2016. Ms. Dutta brings 19 years of human resources experience including organizational development, strategy, recruiting, and employee relations, joining Corindus from AMAG Pharmaceuticals where she served as Senior Director of Human Resources. In that role, she provided strategic leadership on a transformational acquisition, was a member of the senior management team for its Hematology and Oncology Division and lead AMAG’s HR Operations and Recruitment functions. Previously, Ms. Dutta served as a Strategic HR Business Partner to the Global Strategy, Marketing and Business Services functions at Boston Scientific. She was also a key team member on numerous acquisitions and strategic business initiatives over her 8-year tenure with Boston Scientific.

Mr. Teany and Ms. Dutta will be part of the Corindus senior leadership team, reporting directly to Mark Toland, President and Chief Executive Officer.

"We are delighted to bring in two leaders with highly relevant experience and a long track record of successfully building high-performing teams and establishing organizational excellence," said Toland. “We welcome Doug and Nora to our team, and look forward to their many contributions as we enter this next stage of growth."

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.